Evidence map›Paper›PMID 26277582›Full record

ArticleExperimental eye research2015

Programmed cell death-1 is expressed in large retinal ganglion cells and is upregulated after optic nerve crush.

Wei Wang, Ann Chan, Yu Qin, Jacky M K Kwong, Joseph Caprioli, Ralph Levinson, Ling Chen, Lynn K Gordon

Abstract read
In one paragraph

Article in Experimental eye research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Expression and T cell regulatory action of the PD-1 immune checkpoint in the ovary and fallopian tube.American journal of reproductive immunology (New York, N.Y. : 1989) · 2023
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Modulation ofRNA biology · 2019
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Wei WangJules Stein Eye Institute, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, United States; Fudan Affiliated Eye and ENT Hospital, Fenyang Road 83#, Shanghai 200031, China.
Ann ChanJules Stein Eye Institute, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, United States.
Yu QinJules Stein Eye Institute, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, United States.
Jacky M K KwongJules Stein Eye Institute, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, United States.
Joseph CaprioliJules Stein Eye Institute, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, United States.
Ralph LevinsonJules Stein Eye Institute, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, United States.
Ling ChenJules Stein Eye Institute, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, United States; Fudan Affiliated Eye and ENT Hospital, Fenyang Road 83#, Shanghai 200031, China. Electronic address: linglingchen98@hotmail.com.
Lynn K GordonJules Stein Eye Institute, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095, United States. Electronic address: lgordon@mednet.ucla.edu.
Doheny Eye Institute · USUniversity of California, Los Angeles · US

Funding

Vision Research Core at UCLAP30EY000331 · NEI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Gregory Darin Field, DAVID S WILLIAMS · 1985 to 2026
$16.8M
NEI NIH HHS EY00331NEI NIH HHS P30 EY000331
6 · The paper itself

Abstract

Programmed cell death-1 (PD-1) is a key negative receptor inducibly expressed on T cells, B cells and dendritic cells. It was discovered on T cells undergoing classical programmed cell death. Studies showed that PD-1 ligation promotes retinal ganglion cell (RGC) death during retinal development. The purpose of this present study is to characterize PD-1 regulation in the retina after optic nerve crush (ONC). C57BL/6 mice were subjected to ONC and RGC loss was monitored by immunolabelling with RNA-binding protein with multiple splicing (Rbpms). Time course of PD-1 mRNA expression was determined by real-time PCR. PD-1 expression was detected with anti-PD-1 antibody on whole mount retinas. PD-1 staining intensity was quantitated. Colocalization of PD-1 and cleaved-caspase-3 after ONC was analyzed. Real-time PCR results demonstrated that PD-1 gene expression was significantly upregulated at day 1, 3, 7, 10 and 14 after ONC. Immunofluorescent staining revealed a dramatic increase of PD-1 expression following ONC. In both control and injured retinas, PD-1 tended to be up-expressed in a subtype of RGCs, whose somata size were significantly larger than others. Compared to control, PD-1 intensity in large RGCs was increased by 82% in the injured retina. None of the large RGCs expressed cleaved-caspase-3 at day 5 after ONC. Our work presents the first evidence of PD-1 induction in RGCs after ONC. This observation supports further investigation into the role of PD-1 expression during RGC death or survival following injury.

Indexed as

AnimalsApoptosisCaspase 3Disease Models, AnimalFluorescent Antibody Technique, IndirectGene Expression RegulationMiceMice, Inbred C57BLNerve CrushOptic Nerve InjuriesProgrammed Cell Death 1 ReceptorReal-Time Polymerase Chain ReactionRetinal Ganglion CellsRNA, MessengerSignal TransductionCasp3 protein, mouseCaspase 3Pdcd1 protein, mouseProgrammed Cell Death 1 ReceptorRNA, MessengerApoptosisLarge retinal ganglion cellsNeuroprotectionOptic nerve crushProgrammed cell death-1

Identifiers

PMID26277582
PMCPMC5420326
OpenAlexW1125118321

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.